The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. The ability of mutant p53 to bind ...

They reported an RNA aptamer-based PROTAC degrader capable of targeting and degrading the p53-R175H mutant previously. However, the serum instability limits its clinical translation. In this study ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...

Some gain-of-function phenotypes of mutant p53 may result from the loss of multiple functions rather than novel functions. This aggregation effect, alongside impaired tetramer formation ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

In August 2024, Elicio received a $1.5M grant from the Gastro-Intestinal Research Foundation to support continued development of vaccines targeting p53 and BRAF mutations. In July 2024, a $11.5M ...

"Based on proof-of-concept data demonstrating the ability of rezatapopt to selectively reactivate p53 in locally advanced/metastatic solid tumor patients with a TP53 Y220C mutation, we believe that ...

EGFR Mutation Testing on Cytological and Histological Samples in ... Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int.

In the field of myelodysplastic syndromes (MDS), there are a number of investigational studies designed with the hope of ...

tumor-agnostic therapies targeting p53, today provided an update on the Phase 2 monotherapy and Phase 1b combination portions of the ongoing PYNNACLE clinical trial. PYNNACLE Phase 2 Monotherapy ...